Clinical trials: Psoriasis Patients
Psoriasis
Duobrii in Combination With Biologics
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
- Trial name
- NCT04119102
- Testing
- Duobrii
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Arthritis, Psoriatic
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis.
- Trial name
- NCT05640245
- Testing
- Sonelokimab, Adalimumab
- Where
- 42 sites in United States, Bulgaria and 6 more
- Volunteers
- 207 people
- Sponsor
- MoonLake Immunotherapeutics AG
Psoriasis
Proton Pump Inhibitors Use in Patients With Psoriasis
Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients…
- Trial name
- NCT02624544
- Testing
- esomeprazole, desonide
- Sponsor
- EMS
Psoriasis
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety Secondary objectives of Part 1 are to evaluate…
- Trial name
- NCT03635099
- Testing
- BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted)
- Where
- 34 sites in United States, Canada and 1 more
- Volunteers
- 274 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis
This is an observational safety study tracking psoriasis patients on etanercept (Enbrel) for 5 years.
- Trial name
- NCT00322439
- Testing
- Etanercept
- Volunteers
- 2,511 people
- Sponsor
- Amgen
Psoriasis
A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan
The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.
- Trial name
- NCT05633264
- Where
- Japan
- Volunteers
- 369 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With Psoriasis
This trial is a Phase IIa clinical trial. Around 65 subjects will be enrolled into this study to primarily assess the treatment efficacy of 5% GM-XANTHO in patients with psoriasis, as well as the safety and tolerability of 5%…
- Trial name
- NCT06620692
- Testing
- 5% GM-XANTHO [GM-XAN003]
- Volunteers
- 65 people
- Sponsor
- Xantho Biotechnology Co., LTD
Arthritis, Psoriatic
Single Dose PG102 in Patients With Active Psoriatic Arthritis
The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis.
- Trial name
- NCT00787137
- Testing
- PG102
- Where
- Serbia
- Volunteers
- 17 people
- Sponsor
- PanGenetics UK Limited
Plaque Type Psorisis
Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
- Trial name
- NCT06742957
- Testing
- Tapinarof Cream 1%, VTAMA®
- Where
- 26 sites in United States
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Psoriatic Arthritis
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an…
- Trial name
- EVOLUTION (NCT05669833)
- Testing
- Guselkumab, Golimumab
- Where
- 14 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
Psoriasis
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel with no active ingredients as treatment for their scalp psoriasis for 8 weeks.
- Trial name
- NCT00279162
- Testing
- Calcipotriene/betamethasone gel and ointment
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- LEO Pharma
Psoriasis, Inflammation
Subclinical Impairment of Cardiovascular System in Patients With Psoriasis
A cross-sectional study will be conducted, which will include 80 young patients with psoriasis, aged 30-45 years, treated with five different types of antipsoriatic treatment, and 20 healthy patients.
- Conditions
- Psoriasis, Inflammation, Endothelial Dysfunction, Metabolic Disturbance
- Trial name
- PaS (NCT05957120)
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- University Medical Centre Ljubljana
Guttate Psoriasis
Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis
The goal of this clinical trial is to analyse efficacy and safety of ixekizumab in participants with refractory guttate psoriasis.
- Trial name
- NCT06374979
- Testing
- Ixekizumab
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Psoriasis
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.
- Trial name
- UNCOVER-1 (NCT01474512)
- Testing
- 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 1,296 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Quality of Life
Psoriasis and Its Impact on Quality of Life Among Psoriatic Patients
This work aimed to study some epidemiological features and the clinical profile of patients having psoriasis visiting the Dermatology and Venereology departments of Tanta University Hospitals and to assess the impact of disease…
- Trial name
- NCT07709169
- Testing
- Quality of Life assessment
- Where
- Egypt
- Volunteers
- 170 people
- Sponsor
- Tanta University
Psoriasis, Etanercept
the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis
This is a prospective, open-label, one-arm study. The study aims to assess the efficacy and safety of Etanercept therapy which help guide the clinical practice in real-world settings.
- Trial name
- NCT04912401
- Where
- 40 sites in China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Spondylitis, Ankylosing, Arthritis, Rheumatoid
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
The purpose of this observational study is to evaluate the safety and effectiveness of infliximab injection under actual conditions of use in participants, and to learn more about its adverse events.
- Conditions
- Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic
- Trial name
- NCT00760669
- Testing
- Infliximab; observational study, Methotrexate; observational study
- Volunteers
- 1,061 people
- Sponsor
- Janssen Korea, Ltd., Korea
Vulgaris Psoriasis
A Clinical Study of Subclinical Enthesitis and Synovitis in Patients With Vulgaris Psoriasis
A clinical study of subclinical enthesitis and synovitis in patients with vulgaris psoriasis
- Trial name
- NCT02339636
- Testing
- PDUS examination
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The 306 Hospital of People's Liberation Army
Psoriasis
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of risankizumab (BI 655066) to support registration for…
- Trial name
- NCT02684357
- Testing
- risankizumab, ustekinumab
- Volunteers
- 577 people
- Sponsor
- AbbVie
Plaque Psoriasis
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis.
- Trial name
- UNCOVER-A (NCT01777191)
- Testing
- Ixekizumab Auto-Injector, Ixekizumab Prefilled Syringe
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.